Relevance of a complete re-resection of contrast enhancing tumor in MGMT promotor non-methylated versus methylated recurrent glioblastomas.

Brain Spine · 2026 · PMC13129442 · PMID 42079380

Europe PMC DOI

hedged sentences

0.0550

closest p · 1.1× alpha

0.2000

boldest claim

The sentences

showed a trendp = 0.055so close (0.05 < p ≤ 0.1)

3.02 months; p = 0.0064) and showed a trend toward better OS (p = 0.055).

also in 53,322 other papers

a trend toward significancep = 0.055so close (0.05 < p ≤ 0.1)

When stratified by MGMT status and extent of re-resection, a trend toward significance was observed ( p = 0.055; Fig. 2 C).

also in 3,729 other papers

did not reach statistical significancep = 0.20not close (p > 0.1)

Reoperation survival (RS) analysis showed a trend toward improved outcomes in MGMT-methylated patients (median 9.6 months) compared with non-methylated patients (median 7.3 months), though this did not reach statistical significance ( p = 0.20; Fig. 2 E).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.